$70M Upfront Payment Secured by BioCryst in European Navenibart Licensing Deal
BCRX sits 55% above its 52-week low of $6.
Summary
BioCryst Pharmaceuticals has entered a European licensing agreement with an Irish affiliate of Neopharmed Gentili for its investigational hereditary angioedema (HAE) drug, navenibart. The deal includes a significant $70 million upfront payment to BioCryst, with potential for up to $275 million in future regulatory and sales milestones, plus tiered royalties of 18% to 30% on net sales. This agreement, which follows an 8-K filing confirming the transaction, strengthens BioCryst's financial position and leverages an existing partnership, allowing the company to optimize its commercial focus while retaining substantial upside from a key pipeline asset. This is a material positive development, providing capital and a clear path for European commercialization of navenibart, which is currently in Phase 3 with a US regulatory filing targeted by the end of 2027.
At the time of this announcement, BCRX was trading at $9.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $6.00 to $11.31. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.